Nextgen In-Vitro Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 4.05 Cr
as on 14-12-2024
- Paid Up Capital ₹ 1.88 Cr
as on 14-12-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Nextgen In-Vitro Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.05 Cr and a paid-up capital of Rs 1.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sushil Mehta, Devashish Ohri, Ashok Jain, and Two other members serve as directors at the Company.
- CIN/LLPIN
U33110DL2015PTC279481
- Company No.
279481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nextgen In-Vitro Diagnostics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devashish Ohri  | Managing Director | 12-Aug-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sushil Mehta | Director | 12-Oct-2016 | Current |
| Ashok Jain | Director | 02-Mar-2020 | Current |
| Pankaj Krishna | Director | 19-Dec-2023 | Current |
| Varun Chopra | Director | 24-Apr-2015 | Current |
Financial Performance and Corporate Structure Insights of Nextgen In-Vitro Diagnostics.
Nextgen In-Vitro Diagnostics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nextgen In-Vitro Diagnostics?
In 2023, Nextgen In-Vitro Diagnostics had a promoter holding of 80.33% and a public holding of 19.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nextgen In-Vitro Diagnostics?
Unlock and access historical data on people associated with Nextgen In-Vitro Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nextgen In-Vitro Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextgen In-Vitro Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
